Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (Diluted Average) (2020 - 2025)

Keros Therapeutics filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $37.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.13% to $37.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.9 million, a 1.13% increase, with the full-year FY2025 number at $37.9 million, up 1.13% from a year prior.
  • Shares Outstanding (Diluted Average) hit $37.9 million in Q4 2025 for Keros Therapeutics, down from $40.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $41.2 million in Q2 2025 to a low of $23.2 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $29.5 million (2023), compared with a mean of $30.8 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 131.43% in 2021 and later increased 1.13% in 2025.
  • Keros Therapeutics' Shares Outstanding (Diluted Average) stood at $23.3 million in 2021, then rose by 8.17% to $25.2 million in 2022, then grew by 16.66% to $29.4 million in 2023, then increased by 27.14% to $37.4 million in 2024, then grew by 1.13% to $37.9 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $37.9 million (Q4 2025), $40.6 million (Q3 2025), and $41.2 million (Q2 2025) per Business Quant data.